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OBJECTIVE—The physiologic signiﬁcance of the nitric oxide
(NO)/cGMP signaling pathway in islets is unclear. We hypothe-
sized that cGMP-dependent protein kinase type I (cGKI) is
directly involved in the secretion of islet hormones and glucose
homeostasis.
RESEARCH DESIGN AND METHODS—Gene-targeted mice
that lack cGKI in islets (conventional cGKI mutants and cGKI
and I rescue mice [/RM] that express cGKI only in smooth
muscle) were studied in comparison to control (CTR) mice. cGKI
expression was mapped in the endocrine pancreas by Western
blot, immuno-histochemistry, and islet-speciﬁc recombination
analysis. Insulin, glucagon secretion, and cytosolic Ca
2
([Ca
2]i) were assayed by radioimmunoassay and FURA-2 mea-
surements, respectively. Serum levels of islet hormones were
analyzed at fasting and upon glucose challenge (2 g/kg) in vivo.
RESULTS—Immunohistochemistry showed that cGKI is present
in - but not in -cells in islets of Langerhans. Mice that lack
-cell cGKI had signiﬁcantly elevated fasting glucose and gluca-
gon levels, whereas serum insulin levels were unchanged. High
glucose concentrations strongly suppressed the glucagon release
in CTR mice, but had only a moderate effect on islets that lacked
cGKI. 8-Br-cGMP reduced stimulated [Ca
2]i levels and glucagon
release rates of CTR islets at 0.5 mmol/l glucose, but was without
effect on [Ca
2]i or hormone release in cGKI-deﬁcient islets.
CONCLUSIONS—We propose that cGKI modulates glucagon
release by suppression of [Ca
2]i in -cells. Diabetes 60:
148–156, 2011
T
he complex and tightly controlled process of
glucagon secretion from pancreatic -cells is
important for the maintenance of blood glucose
homeostasis (1). Glucagon release is physiolog-
ically regulated by multiple signaling pathways that in-
clude neuronal control of -cell function, paracrine factors
such as insulin (2,3), and/or -aminobutyric acid (GABA)
(4) released from -cells, somatostatin (SST) secreted
from adjacent -cells (5), and the inhibitory role of high
blood glucose itself that directly acts on -cells to sup-
presses glucagon release (3,6).
Controversial data have been reported for the physio-
logic signiﬁcance of the nitric oxide (NO) pathway for islet
functions. Both types of constitutive NOS (eNOS, nNOS)
isozymes have been identiﬁed in islets (7–11). It was
suggested that NO stimulates glucose-induced insulin re-
lease (7,10), was a negative modulator of insulin release
(8,12,13) or had no effect (14). These discrepant results are
probably caused by the analysis of various -cell–derived
cell lines compared with intact islets, the use of different
types and concentrations of NO-donors and NOS-inhibi-
tors. Additional data suggested that iNOS-derived NO is
involved in autoimmune reactions that cause -cell–dys-
function leading to insulin-dependent diabetes (15,16).
It has been difﬁcult to discriminate between a direct
action of NO on -cells and an indirect effect of NO via
-cells since -cell factors are potent inhibitors of -cell
activity (12,17,18). An important target of NO is the soluble
guanylyl cyclase (sGC) that generates the second messen-
ger cyclic guanosine-3-5-monophosphate (cGMP) (19).
Some studies detected increased islet cGMP levels upon
treatment with cytokines and L-arginine (12,15,20). cGMP
analogues were reported to potentiate insulin release
directly (21), suggesting that cGMP-dependent effectors
are involved in the control of islet activity. The cGMP-
dependent protein kinase type I (cGKI) is an important
intracellular mediator of NO/cGMP signaling in many cells
(22). The analysis of cGKI-deﬁcient mice revealed that
cGKI mediates the inhibitory effects of NO on platelet
aggregation, the negative inotropic effect of NO/cGMP in
the murine heart, and the NO-induced relaxation of blood
vessels (22). However, cGKI knockout mice could not be
analyzed reliably for a distorted islet function because
they display abnormalities of various organ systems and
die within the ﬁrst 6 weeks (23). Recently, we generated an
improved mouse model to study the speciﬁc roles of cGKI
in vivo (24,25). These mice express either the cGKI or
cGKI isozyme selectively in smooth muscle cells (SMCs)
on a cGKI-deﬁcient genetic background. Since the animals
show a prolonged life expectancy and normal SMC func-
tions they were termed cGKI and cGKI rescue mice
(RM and RM, respectively).
We examined the role of cGKI for the regulation of
glucose homeostasis using cGKI-KO mice (23) and rescue
mice (RM) (24,25) models. We show that cGKI is ex-
pressed in the -cells of the endocrine pancreas, whereas
in different gene-targeted animals the cGKI protein was
not detectable. Furthermore, we demonstrate that islet
cGKI regulates glucagon release by modulation of the
glucose-dependent changes of [Ca
2]i that trigger exocy-
tosis. These ex-vivo ﬁndings were supported by elevated
serum levels of basal glucose and glucagon in intact RM
animals.
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Experimental animals. The generation of the conventional cGKI-knockout
mice (cGKI-KO; genotype: cGKI
L/L) (23) and cGKI and I rescue animals
(RM; genotype: SM22
/I; cGKI
L/L and RM; genotype: SM22
/I;
cGKI
L/L) has been described (25). All animals were maintained and bred in
the animal facility of the Institut fu ¨r Pharmakologie und Toxikologie, Tech-
nische Universita ¨tMu ¨nchen and had free access to water and standard chow.
The experimental procedures were approved by the local government’s
Committee on Animal Care and Welfare in Oberbayern. For in vivo experi-
ments, male gene-targeted cGKI animals were used and compared with their
age and littermate controls on a 129Sv inbred background (CTR; genotype:
cGKI
/L and/or cGKI
/). The GLUC-Cre mouse (26) and the RIP-Cre mouse
(27) were crossed to mice that carry loxP-ﬂanked cGKI alleles (L2) (28) to
generate cGKI mutants with recombined cGKI-null alleles (L)i n or -cells,
respectively. The tissue-speciﬁc cGKI knockouts on a C57/BL6N genetic
background were termed “-cell cGKI knockout” (cGKI
acko; genotype: GLUC-
Cre
tg/; cGKI
L/L2) and “-cell cGKI knockout” (cGKI
bcko, genotype: RIP-
Cre
tg/; cGKI
L/L2). For experiments the cGKI
acko and cGKI
bcko mice were
compared with littermate controls (genotype: GLUC-Cre
tg/; cGKI
/L2 and
RIP-Cre
tg/; cGKI
/L2). The R26-stop-eYFP reporter mice were from the
Jackson Laboratory strain# 006148. Upon Cre-mediated excision of an inter-
vening stop sequence, eYFP was expressed in -cells of GLUC-Cre
tg/;
eYFP
tg/ mice.
Determination of body fat. We compared 5- to 6-week-old cGKI-KO mice
and 15- to 20-week-old RM mice with their littermate controls. Mice were
killed by cervical dislocation and weighed (wet weight). The water fraction
was extracted by incubation of the bodies at 90°C for 24 h. The dried
mummies were weighed (dry weight), homogenized, and then transferred to
an extraction sleeve. The body fat was extracted by chloroform used as a
organic solvent in a soxhlet apparatus After ﬁve extraction cycles, the
nonsoluble portion remained in the sleeve and the extracted fat was collected
in the chloroform. The sleeves were dried for 12 h at 90°C and weighed again.
The body fat content was the weight difference of the mummiﬁed bodies
before and after the soxhlet extraction.
Serum hormone determinations. The 96-well ﬂuorescent LINCOplex mi-
croplate immunoassay (Millipore) was used to determine simultaneously the
concentrations of glucagon and insulin in 10 l mouse serum in the presence
of dipeptidyl peptidase IV inhibitors and aprotinin. A combination of ﬂuores-
cent beads that bind to glucagon or insulin-speciﬁc antibodies and biotinyl-
ated detection antibodies allow for a speciﬁc quantiﬁcation of the islet
hormones. The assay was performed according to the manufacturers recom-
mendations and then quantiﬁed in a Bio-Plex micro-plate reader.
Isolation of islets. Islets were isolated according to previous studies (29). In
brief, islets were isolated by the retrograde injection of a digestion solution
(1.9 units/ml collagenase/HBSS; Sigma Aldrich) into the pancreas. Islets were
puriﬁed by several washings, picked by hand, and transferred to culture
medium (RPMI-1640, 5 mmol/l glucose, 100 units/ml penicillin, 100 g/ml
streptomycin, 10% FCS). The protein/RNA extractions were performed on
pooled islets isolated from 3 to 6 animals.
Western blot analysis. Overnight-cultured islets were thoroughly rinsed by
three changes of PBS and then homogenized in 50 l protein lysis buffer (20
mmol/l Tris-HCl, pH 8.3; 0.67% SDS; 238 mmol/l -mercaptoethanol; 0.2 mmol/l
PMSF). Proteins obtained from 100 islets were separated on 8% SDS-
polyacrylamide gels. Immunodetection was performed by using the primary
antibodies speciﬁc for cGKI common (30) (dilution 1:200), cGKI (30)
(dilution 1:500), cGKI (30) (dilution 1:500), -actin (Abcam) (dilution
1:10,000), PDE-5 (24) (dilution 1:500), inositol 1,4,5,-triphosphate receptor
associated cGMP kinase substrate (IRAG) (30) (dilution 1:300), or somatosta-
tin (Santa-Cruz) (dilution 1:2,000).
Immunohistochemistry and ﬂuorescence. Immunodetection was per-
formed on parafﬁn-embedded serial 8- to 10-m sections of the pancreas as
previously published (24). Biotinylated secondary antibodies (1:200 dilution;
Vector Laboratories) in combination with the avidin-biotin method (Vector
Laboratories) were used to identify primary antibody/antigen complexes by
immunohistochemistry. Visualization of the immune complexes was carried
out by Vector Blue substrate (Vector Laboratories) or diaminobenzidine
(brown staining) (Sigma-Aldrich).
Alternatively, primary antibody/antigen complexes were detected with
secondary antibodies conjugated to ﬂuorescent dyes (1:200 dilution, Dianova),
and then the ﬂuorescence signals were visualized by a confocal laser scanning
microscope (LSM510, Zeiss). Primary antibodies used were speciﬁc for cGKI
(1:50 dilution) (30), cGKI (1:50 dilution) (30), insulin (1:2,500 dilution;
DAKO), glucagon (1:2,000 dilution, Sigma-Aldrich), somatostatin (1:1,000
dilution, Santa-Cruz), and sGC1 (1:200 dilution) (19).
Islet/striated muscle RNA isolation for RT-PCR analysis. After 18–24 h in
culture, islets were thoroughly rinsed by three changes of PBS, transferred to
RNAse-free reaction tubes, and shock frozen in liquid nitrogen. RNA was
extracted by the peqGOLD RNA pure reagent (PEQLab). 500 l peqGOLD
reagent was used for the puriﬁcation of total RNA from 500 islets.
Skeletal muscles from murine hind limbs were used for RT-PCR analysis.
The puriﬁed RNA was dissolved in 50 l diethyl-pyrocarbonate treated ddH2O,
quantiﬁed by standard ultraviolet photometry, and stored at 20°C until
RT-PCR was carried out. The mRNA transcripts coding for cGKI, sGC2,
sGC1, Npr-1 (GC-A), Npr-2 (GC-B), and GLUT4 in islets/striated muscles
were standardized to the mRNA of hypoxanthine phosphoribosyltransferase
(HRPT) coampliﬁed in the same reaction. The primer sequences and the size
of the fragments ampliﬁed were: cGKI (425 bp) forward 5-GGAAGTTCAC
TAAATCCGAGAG-3, reverse 5-TGAGGATTTCATCAGGAAGG-3; sGC2
(303 bp) forward 5-AGATGCTCCTATGCAGACC-3, reverse 5-CATCAGAG
TACCTTCAGGAAGC-3; sGC1 (251 bp) forward 5-AGCCCTTACACCTT;
CTGC-3, reverse 5-CACTCAAGTTTCTCCACATCC-3; Npr-1 (357 bp) for-
ward 5-AGGCGCTTGTGCTCTATG-3, reverse 5-TATCCTGCCCATCGTCTC-
3; Npr-2 (364 bp) forward 5-AGCCATGCCCTCTATGC-3, reverse 5-ATATG
CTGGTACCACCTTCC-3; GLUT4 (381 bp) forward 5-TCGTCATTGGCAT
TCTGGT-3, reverse 5-CATTGATGCCTGAGAGCTGTT-3; HPRT (175 bp)
forward 5-GTAATGATCAGTCAACGGGGGAC-3, reverse 5-TGGTTAAGGTTG
CAA GCTTGCTGG-3.
Ex-vivo islet glucagon/insulin release. Freshly isolated islets were prein-
cubated for 30 min at 37°C in a Krebs-Ringer buffer (KRB) at pH 7.4 containing
in mmol/l: 120 NaCl, 25 NaHCO3, 4.7 KCl, 1.2 MgSO4, 2.5 CaCl2, 1.2 KH2PO4,5
glucose, 10 HEPES and 1 mg/ml BSA. Groups of 10 and 20 islets were
incubated for 60 min at 37°C in 200-l KRB buffer for the determination of
insulin or glucagon, respectively.
Ca
2 imaging. Freshly isolated islets were incubated in a humidiﬁed incuba-
tor for 4 h. Islets were loaded with 10 mol/l Fura-2AM (Calbiochem) in KRB
buffer at 37°C for 30 min. Thereafter, islets were washed and then perfused
with bath solution at 1 ml/min at 37°C in a chamber on the microscope stage.
Experiments were performed using a Zeiss microscope with a Zeiss Fluor 205
40	 objective and a cooled charge-coupled device camera. Dual excitation at
340/380 nm was used and emission at 510 nm measured (TILLviSION software,
Till Photonics, Gra ¨felﬁng, Germany). Every 700 ms, 20 ms exposures were
taken. The frequency of changes in the [Ca
2]i oscillations and the peak
amplitudes were determined and normalized to the 340/380 nm ratios. Only
cells displaying a distinct response to 5 and 0.5 mmol/l glucose or 20 mmol/l
glucose were included in these calculations.
RESULTS
Basal glucose homeostasis in cGKI gene-targeted
mice. To investigate whether physiologic glucose ho-
meostasis in the intact animal depends on the presence of
cGKI, we used three gene-targeted models of cGKI deﬁ-
ciency, i.e., conventional cGKI knockout mice (cGKI-KO)
that do not express the cGKI isozymes in any cell (23) and
mice that express either the cGKI or cGKI (RM and
RM, respectively) isozyme under the control of the
endogenous SM22 promoter speciﬁcally in SMCs on a
cGKI-deﬁcient background (24,25). Serum glucose concen-
trations were signiﬁcantly higher after 12-h fasting in the
cGKI-KO (Fig. 1A), RM (Fig. 1B), and RM than in the
CTR mice. Fasting blood glucose levels were 45.5 
 1.5
mg/dl (n  12) in 6- to 8- week-old CTR mice, 61.4 
 2.9
mg/dl (n  9) in 6- to 8-week-old cGKI-KO mice, 71.8 

2.3 mg/dl (n  18) in 15- to 20-week-old RM mice,
90.7 
 3.2 mg/dl (n  26) in 15- to 20-week-old RM
mice, and 57.4 
 1.3 mg/dl (n  53) in age-matched CTR
mice. Since these results suggested that RM and
RM mice had an identical hyperglycemic phenotype, we
used RM mice for further experiments. The glucagon
serum concentrations were signiﬁcantly elevated in RM
(22.3 
 3.6 pmol/l; n  8) compared with CTR mice (CTR
15.2 
 1.8 pmol/l; n  21) (Fig. 1C). Interestingly, basal
serum insulin levels did not differ between the two geno-
types (Fig. 1D). These ﬁndings suggest that cGKI is in-
volved in the control of glucose homeostasis at fasting.
In vivo glucose and insulin tolerance. We performed
insulin and oral glucose tolerance test (OGTT) to examine
whether the elevated glucose and glucagon levels in the
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targeted mice. We induced hypoglycemia by intraperito-
neal injection of insulin. Blood glucose levels were
monitored during 180 min in 12-h fasted RM and CTR
mice. Within 60 min, insulin lowered the blood glucose to
the same minimal level (supplementary Fig. 1 in the online
appendix available at http://diabetes.diabetesjournals.org/
cgi/content/full/db10-0595/DC1.). Both types of mice were
able to counter-regulate the blood glucose levels to phys-
iologic levels within 180 min (supplementary Fig. 1). These
data suggest that glucose handling after a single high dose
of exogenous insulin was not disturbed in RM animals.
In contrast, the OGTT was signiﬁcantly improved in
RM animals as compared with CTR littermates (supple-
mentary Fig. 2A). During the ﬁrst 15 min, blood glucose
levels increased in CTR and RM animals. Blood glucose
levels continued to increase in CTR animals, whereas they
remained constant in RM mice at 30 min, indicating a
faster glucose clearance. Thereafter, blood glucose level
decreased in both animal types and reached 223.7 
 18.3
mg/dl; n  15 and 143 
 20.2 mg/dl; n  11 after 60 min in
CTR and RM mice, respectively. No differences were
detectable between both genotypes at 120 min.
During the entire OGTT, RM animals had higher glu-
cagon levels than CTR mice (supplementary Fig. 2B).
Values were signiﬁcantly higher at 5 min (CTR 13.3 
 1.6
pmol/l; n  8; RM 20.8 
 1.8 pmol/l; n  8), 15 min (CTR
11.6 
 2.3 pmol/l; n  5; RM 18.9 
 1.7 pmol/l; n  8), 30
min (CTR 14.9 
 3.4 pmol/l n  6; RM 17.6 
 1.5 pmol/l
n  7), and 120 min (CTR 12.9 
 2.4 pmol/l n  7; RM
18.6 
 2.2 pmol/l n  8).
In the presence of higher glucose levels (see Fig. 1)
basal insulin levels did not differ between CTR and RM
mice (supplementary Fig. 2C). However, 15 min after
glucose application, serum insulin concentration was
higher in RM than in CTR animals (CTR 68.5 
 12.2
pmol/l; n  11; RM 84 
 19 pmol/l; n  8), but these
values did not reach statistical signiﬁcance.
Since the superior glucose tolerance of RM mice was
not based on an improved glucose-stimulated response of
pancreatic -cells to secrete insulin, we hypothesized that
it must be due to enhanced peripheral insulin sensitivity. It
is known that the gene-targeted cGKI mice weigh less than
their littermate CTRs. Therefore, we tested if the improved
clearance of glucose from the serum was responsible for
the altered OGTT proﬁle. The total body fat mass and
serum lipids were signiﬁcantly lower in cGKI-KO and RM
mice as compared with littermate CTRs (supplementary
Fig. 2D–F). In addition, we found higher levels of the
insulin-dependent glucose transporter 4 (GLUT4) mRNA
in striated muscle preparations (supplementary Fig. 2G).
These results implicate that the OGTT of gene-targeted
cGKI mice was improved indirectly by changes in the body
periphery.
Expression analysis of islet cGKI. Since glucagon se-
cretion was deregulated in cGKI mutant mice, we hypoth-
esized that cGKI may be expressed in the islets. Western
blots identiﬁed the cGKI protein in islets of CTR mice,
whereas no cGKI protein was detectable in the islets of
conventional cGKI-KOs, RM, and RM animals (Fig. 2A).
As reported previously (25), the cGKI protein was present
in the stomach of the RM and RM mice. In contrast,
cGKI expression was not detectable in SMCs and other
organ systems of the cGKI-KO mice (Fig. 2B).
Immunohistochemical analysis mainly identiﬁed cGKI in
a subset of cells that localized to the mantle of the islets
(Fig. 2C). As expected, small vessels containing SMCs
were positively stained for cGKI in CTR, RM, and RM
mice, but remained unstained in cGKI-KO animals (Fig.
2C). Islets of conventional cGKI-KOs, as well as islets of
RM and RM mice were not stained for cGKI, conﬁrming
that they lack the cGKI protein (Fig. 2C). The cGKI-
expressing cells were not stained by an insulin antibody
(24,25,30), indicating that the two proteins were not coex-
pressed in -cells (supplementary Fig. 3A). The insulin
expression pattern of cGKI-deﬁcient islets in cGKI-KO,
RM, and RM animals was not different from the pattern
of CTR islets (supplementary Fig. 3A). A subpopulation of
-cells that were detected by the -cell marker SST showed
colocalization of SST and cGKI (supplementary Fig. 3B).
However, in most SST-positive cells, cGKI was absent. SST
expression was not altered in the different cGKI-deﬁcient
islets (supplementary Fig. 3B). High-resolution immuno-
ﬂuorescence experiments clearly demonstrated colocal-
ization of cGKI and glucagon in all -cells (Fig. 3). Again,
the cGKI protein was not detected in cGKI-deﬁcient
islets of cGKI-KO, RM, and RM mice, whereas the
quantity and intensity of glucagon-stained cells was
similar. The absence of the cGKI protein did not affect
the size and the number of islets per pancreatic cross-
section area, the amount of cells per islets, and their
cellular combination (data not shown).
To support the observation that cGKI is expressed in
-but not in -cells, we used the RIP-Cre mouse, which is
able to generate efﬁcient -cell-speciﬁc inactivation of
A B
C D
FIG. 1. Basal blood glucose and serum hormone levels of mice lacking
cGKI in islets after 12-h fasting. A: Basal blood glucose levels deter-
mined from 6- to 8-week-old cGKI-KO (ko) mice and their littermate
controls (ctr). B: Basal blood glucose levels measured in 15- to
30-week-old RM and control (ctr) mice. C: The average serum gluca-
gon levels of fasted RM were signiﬁcantly increased in comparison
with CTRs. D: The analysis of serum insulin revealed no differences
between RM compared with littermate controls (***P < 0.001). (A
high-quality color representation of this ﬁgure is available in the
online issue.)
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ﬂoxed cGKI mouse line (28) and generated the -cell–
speciﬁc cGKI-knockouts (cGKI
bcko). Expression of cGKI
was unchanged in islets of cGKI
bcko mice, conﬁrming that
cGKI is not present in -cells (supplementary Fig. 4A).
Basal fasting glucose levels of cGKI
bcko mice were not
different from their respective controls (supplementary
Fig. 4B). Vice versa, we used the GLUC-Cre mouse ex-
pressing the Cre recombinase speciﬁcally in -cells (26).
Mating of the GLUC-Cre mice with the ﬂoxed cGKI ani-
mals generated -cell cGKI knockouts (cGKI
acko). In com-
parison with age and littermate controls, no increase of
the basal glucose was noted in cGKI
acko mice (supplemen-
tary Fig. 4D). We anticipated that the ablation of cGKI in
-cells was inadequate to produce hyperglycemia in vivo.
Indeed, protein levels of islet cGKI in cGKI
acko were
reduced but not depleted (supplementary Fig. 4C), proba-
bly because cGKI was still present in some -cells, caused
by 1) a patchy recombination process, and 2) the presence
of cGKI in -cells (see supplementary Fig. 3B and C).
Together these results indicate that cGKI is expressed in
islet -cells of the mouse and might therefore affect the
synthesis or release of glucagon.
Analysis of cGKI isoforms, target proteins, and key
components for cGMP synthesis. Two distinct isoforms
of cGKI, I and I, are present in different tissues. Western
blot analysis of islet protein homogenates identiﬁed only
the I protein in control islets (supplementary Fig. 5A). As
expected, the cGKI protein was not detectable in the
gene-targeted cGKI animals (supplementary Fig. 5A). In
line with the absence of the cGKI isoform, the cGKI-
speciﬁc target inositol 1,4,5-triphosphate receptor associ-
ated cGMP kinase substrate (IRAG) was not detectable in
pancreatic islets, whereas the cGMP-speciﬁc phosphodies-
terase-5 (PDE-5) was present in the same protein homog-
enates (supplementary Fig. 5A). These results excluded
possible false-positive cGKI signals in the islet protein
samples caused by a contamination with platelets or blood
vessels, since both express mainly the cGKI isoform (30).
In line with the immunoblot data (supplementary Fig. 5A),
A B
C
FIG. 2. cGKI is expression in pancreatic islets. A: The cGKI protein was present in islet lysates of control (CTR, genotype: cGKI
/ or cGKI
/L)
islets but not detectable in islet homogenates from cGKI-KO (KO, genotype: cGKI
L/L), RM (genotype: SM22
/I; cGKI
L/L) and RM
(genotype: SM22
/I; cGKI
L/L) mice. A cGKI common antibody (cGKIcom) (30) was used to identify the respective protein. -actin was used
as loading control and somatostatin (sst) as a marker of pancreatic islets. B: Western blot analysis demonstrating expression of the cGKI protein
in the stomach of control (ctr), RM, and RM mice, but no expression in cGKI-KO (KO) mice. -actin was used as loading control. C:
Immunohistochemical stainings of cGKI protein showing expression in control islets (dotted line) and smooth muscle cells (SMCs) of small blood
vessels (arrows). Pancreatic sections from RM and RM animals show cGKI expression in the exocrine pancreas that was restricted to the
vasculature (arrows), whereas the cGKI-KO pancreatic sections completely lacked the cGKI protein in both islets and SMCs. For better
illustration, a white dotted line was added to indicate the islet’s perimeter. Scale bar, 20 m. (A high-quality color representation of this ﬁgure
is available in the online issue.)
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antibody and semiquantitative RT-PCR analysis using a
cGKI-speciﬁc primer pair conﬁrmed that the cGKI posi-
tive cells (Fig. 2C) expressed the I isozyme (supplemen-
tary Fig. 5B and C).
In general, cGKI is activated by increased cGMP levels.
Therefore, we analyzed the expression of soluble and
particulate guanylyl cyclases (sGC and pGC, respectively)
using cDNA templates generated from puriﬁed islet total
RNA of control animals. We identiﬁed the transcripts for
the natriuretic peptide receptor-1 (NPR-1/pGC-A) and
NPR-2/pGC-B in islets (supplementary Fig. 6A). In addi-
tion, the 1 and 2 subunit of the sGC were expressed in
islets, indicating that a functional NO-sensitive cyclase
might be formed (supplementary Fig. 6B). Immunoﬂuores-
cence analysis revealed that the catalytic 1 subunit of the
sGC speciﬁcally localized to the glucagon positive -cells
(supplementary Fig. 6C). These data suggest that cGMP
accumulation and subsequent activation of cGKI in islets
can be attained by both the NO/sGC and the NP/pGC
pathways (31,32).
Ex vivo insulin/glucagon secretion. The results pre-
sented so far suggest that the gene-targeted cGKI mice
lack cGKI in -cells. The observed changes in glucagon
secretion and glucose homeostasis might therefore be
related to the absence of cGKI in islets. To test this
hypothesis, we determined glucagon secretion in isolated
islets. The mean total glucagon content was not different
between CTR (2.82 
 0.1 ng/islet; n  23), cGKI-KO (3.1 

0.14 ng/islet; n  20), and RM (2.3 
 0.8 ng/islet; n  21)
islets. The cGKI negative islets exposed to 6 mmol/l
glucose released signiﬁcantly more glucagon than CTR
islets (CTR 2.7 
 0.4 pg/islet/h; KO 4.7 
 0.5 pg/islet/h,
RM 4.9 
 0.5 pg/islet/h) (Fig. 4A). In our ex-vivo experi-
ments, we did not notice maximal inhibition of glucagon
release at moderate glucose concentrations (around 7
mmol/l) (33) since glucagon secretion from both CTR and
cGKI-KO islets was further suppressed after exposure to
20 mmol/l glucose (1,3,6). In agreement with the data from
intact animals (see Fig. 1C and supplementary Fig. 2B), the
total glucagon release rates from cGKI negative islets were
still higher (CTR 1.6 
 0.2 pg/islet/h; [n  7] vs. KO 2.6 

0.2 pg/islet/h [n  7]) (Fig. 4A).
In line with the in vivo data (see Fig. 1D and supplemen-
tary Fig. 2C), no differences could be found for the release
of insulin using isolated islets from all three genotypes.
Release rates were similar at 6 mmol/l glucose (CTR
0.15 
 0.02 ng/islet/h; KO 0.13 
 0.09 ng/islet/h, RM
0.22 
 0.03 ng/islet/h) and signiﬁcantly increased to com-
parable levels upon exposure of the islets to 20 mmol/l
glucose (CTR 0.8 
 0.1 ng/islet/h; KO 0.6 
 0.2 ng/islet/h,
RM 0.9 
 0.2 ng/islet/h). The total insulin content of the
islets (in g/islet) was similar for CTR (0.35 
 0.03 (n 
15)) and RM (0.38 
 0.2 (n  21) mice. Taken together,
the ex-vivo hormone secretion experiments demonstrated
that the deletion of cGKI in pancreatic islet cells increased
glucagon releasing rates even at 20 mmol/l glucose.
[Ca
2]i measurements of isolated islets. It is generally
accepted that glucagon release is linked to an increase in
[Ca
2]i (1,34). As recognized for many physiologic pro-
cesses, such as vascular tone, platelet activation, and
synaptic plasticity (22), we hypothesized that cGKI might
interfere with the rise of [Ca
2]i, that triggers glucagon
secretion in -cells. We used genetically-labeled -cells
that expressed the yellow ﬂuorescent protein (eYFP) (35)
to characterize [Ca
2]i signals of individual cells in re-
sponse to glucose changes (supplementary Fig. 7A).
Changes in [Ca
2]i were monitored in FURA-2 loaded
individual islet cells. As expected, glucose-responsive
-cells were inactive at low glucose (0.5–5 mmol/l), but
showed an increase in [Ca
2]i oscillations at 20 mmol/l. In
cGKI glucagon merge
ctr
ko
αRM
cGKI glucagon merge
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FIG. 3. Immunoﬂuorescence analysis of cGKI and glucagon. Colocal-
ization (white arrows) of glucagon (green) and cGKI (red) was
detectable only in islets of control mice (merge). The glucagon signal
in cGKI-KO (KO) and RM animals was well detectable in the mantle of
the islets, but no coexpression with the cGKI protein was found. Scale
bar, 20 m. (A high-quality color representation of this ﬁgure is
available in the online issue.)
A
B
FIG. 4. Insulin and glucagon release from intact islets. A: Glucagon
release from isolated cGKI-KO (KO) islets (red bars) and RM islets
(open bars) was increased at 6 mmol/l as compared with isolated
control islets (black bars). Although control and cGKI-KO islets were
able to decrease glucagon secretion at 20 mmol/l glucose, the glucagon
release was yet signiﬁcantly higher in cGKI-deﬁcient (red bars) islets.
(*P < 0.05). B: Insulin release from isolated cGKI-KO (KO) and RM
islets was unchanged at high (20 mmol/l) and basal (6 mmol/l) glucose
concentrations compared with control (CTR) islets. (A high-quality
color representation of this ﬁgure is available in the online issue.)
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amplitude and frequency of [Ca
2]i at 5 and 0.5 mmol/l,
whereas [Ca
2]i transients were suppressed at 20 mmol/l
glucose (supplementary Fig. 7B) as described earlier for
-cells (1,36). For subsequent experiments, we therefore
used 0.5, 5, and 20 mmol/l glucose, since these concentra-
tions allow discriminating between - and -cells. It was
reported that single -cells in culture do not respond
adequately to glucose when paracrine effects of -cells are
absent (37,38). We therefore performed further analysis of
[Ca
2]i transients in intact islets, which we considered to
be more physiologic. All values are given as ﬂuorescence
ratio of FURA-2 at 340/380 nm and difference of 2 FURA
ratio values (F).
An increase in glucose from 0.5 to 20 mmol/l induced a
signiﬁcant elevation in [Ca
2]i in CTR and cGKI-KO islets
(Fig. 5A and B). The ratio of the FURA-2 values for the
amplitude of the ﬁrst Ca
2-peak (CTR 0.37 
 0.02 n  51;
KO 0.35 
 0.01 n  50), of the oscillations (CTR 0.18 

0.02, n  51; KO 0.17 
 0.02; n  50) (Fig. 5C and D) and
the frequency of the [Ca
2]i oscillations (CTR 0.66 
 0.01
peaks/min; n  51; KO 0.65 
 0.02 peaks/min; n  50) (Fig.
5E) at 20 mmol/l glucose were not different between CTR
and cGKI-KO islets indicating that the -cell response to
the change in glucose concentration did not differ between
the genotypes. At 0.5 and 5 mmol/l glucose (Fig. 6A and B),
concentrations at which only changes of [Ca
2]i in -cells
were observed (see supplementary Fig. 7B and C), the
oscillation frequency of Ca
2-peaks was increased in
cGKI-KO compared with CTR islets (CTR 1.1 
 0.05
peaks/min; n  68, and 0.8 
 0.05 peaks/min; n  68; KO
1.8 
 0.06 peaks/min; n  67 and 2.2 
 0.05 peaks/min;
n  67) (Fig. 6E). These values were signiﬁcant different at
P 
 0.001. Preincubation of islets with 8-Br-cGMP (1
mmol/l), a membrane-permeable analog of cGMP, reduced
the oscillation frequency of the Ca
2-peaks at 0.5 mmol/l
glucose to 0.01 
 0.01 peaks/min (n  30) in CTR -cells,
whereas 8-Br-cGMP had no effect in cGKI-KO islets
(2.11 
 0.04 peaks/min; n  47) (Fig. 6C–E). Furthermore,
we noticed a signiﬁcant increase in the frequency of
[Ca
2]i oscillations in -cells of cGKI-KOs at all glucose
concentrations tested (Fig. 6E).
These experiments indicated that cGKI signiﬁcantly
affected the glucose-induced changes of the [Ca
2]i oscil-
lation of -cells. They suggested that cGKI might also
affect glucagon secretion in CTR -cells if activated by
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FIG. 5. Ca
2 imaging of pancreatic -cells in whole islets. A and B:
Representative changes of [Ca
2]i induced by 20 mmol/l glucose
showed no differences between (A) control (black) and (B) cGKI-KO
(red) islets. C: Average peak amplitude of Ca
2 oscillations at the
initial perfusion of 20 mmol/l glucose and (D) during prolonged
incubation recorded from control (CTR) and cGKI-KO (KO) islets. E:
Peak frequency of Ca
2 oscillations determined in control (CTR) and
cGKI-KO (KO) islets in the presence of 20 mmol/l glucose. In total, 51
CTR and 50 KO cells were analyzed from 10 and 9 individual islets,
which were isolated from 4 CTR and 3 KO mice, respectively. (A
high-quality color representation of this ﬁgure is available in the
online issue.)
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FIG. 6. Ca
2 transients of pancreatic -cells measured in whole islets. A and B: Representative changes in FURA-2 ﬂuorescence ratios at 5 mmol/l
and 0.5 mmol/l glucose measured in control (black) and cGKI-KO (red) islets. C and D: Representative Ca
2-transients measured in the presence
or absence of 8-Br-cGMP (cG; 1 mmol/l) in control (black) and cGKI-KO (red) islets. E: Summary of the experiments shown in A–D. The frequency
of Ca
2 oscillations at 5 mmol/l and 0.5 mmol/l glucose was signiﬁcantly higher in cGKI-KO islets and was not reduced by the addition of
8-Br-cGMP (1 mmol/l). The numbers of cells that were measured under the particular conditions are given in the respective panels. Cells were
from 14 CTR and 9 KO islets isolated from 5 CTR and 3 cGKI-KO mice, respectively. F: The release of glucagon was signiﬁcantly increased in
isolated cGKI-KO (ko) islets (red bars). 8-Br-cGMP (1 mmol/l) had no effect on the release rate of cGKI-KO islets, but suppressed glucagon
release of control (ctr) islets (black bars)( * P < 0.05; ***P < 0.001). (A high-quality color representation of this ﬁgure is available in the online
issue.)
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in islets in the absence and presence of 8-Br-cGMP.
Indeed, 8-Br-cGMP suppressed the release of glucagon in
CTR islets from 7.19 
 0.88 pg/islet/h (n  18) to 3.85 

0.85 pg/islet/h (n  13), whereas it had no effect on KO
islets (12.13 
 2.10 pg/islet/h [n  11] and 14.36 
 2.77
pg/islet/h [n  13]) (Fig. 6F).
DISCUSSION
This manuscript provides novel genetic evidence for the
presence of cGKI in murine islets. We have shown that
cGKI has signiﬁcant functional effects by the following
main ﬁndings: 1) cGKI is expressed in glucagon secreting
-cells and in some SST-positive -cells of the Langerhans
islet; 2) active cGKI decreased glucagon secretion from
islets at 1 mmol/l glucose; 3) active cGKI suppressed
calcium oscillation in -cells at 0.5 mmol/l glucose; and 4)
serum glucose and glucagon levels were higher in the
absence of islet cGKI than in CTR mice after 12-h fasting.
In addition to cGKI, we and others detected several
components of the NO/cGMP and NP/cGMP pathways in
mouse islets, including sGC, pGC, and PDE-5 (20,31).
These ﬁndings establish cGKI as an important signaling
molecule that affects glucose metabolism in the mouse.
It has been shown that ANP inhibited glucagon and
insulin release in isolated rat islets (39,40). Variable results
for NO-donors and NOS inhibitors have been reported
when used at low and high glucose concentrations (7,10).
In line with our results, NO stimulated rat islet cGMP
levels (14,41,42) and inhibited glucagon release most likely
by a cGMP-induced decrease of [Ca
2]i (43), supporting
our observation that the endogenous cGKI suppresses
[Ca
2]i handling and glucagon release.
As recognized for many physiologic processes, such as
vascular tone, platelet activation, and synaptic plasticity
(22), our data indicate that cGKI interferes with the rise of
[Ca
2]i, which is associated with glucagon secretion in
-cells. The molecular mechanism underlying the modula-
tion of glucose-suppressed glucagon release by cGKI is
unknown. Recently, it was implied that the activity of
ATP-dependent K
 (KATP) channels is modulated by re-
combinant cGKI, leading to an increased open probabil-
ity of the channel (44). KATP-channels have been proposed
to play a key role in the regulation of -cell electrical
activity (45,46). According to this hypothesis, -cell elec-
trical activity (and thus glucagon secretion) is only possi-
ble in a narrow window of KATP-channel activity. Both
increased (via membrane hyperpolarization and inhibition
of action potential ﬁring) and decreased KATP-channel (via
membrane depolarization and voltage-dependent inactiva-
tion of the conductances involved in regenerative electri-
cal activity) leads to suppression of glucagon secretion.
However, the regulation of glucagon secretion is more
complicated since it has been shown that exocytosis can
as well be triggered by membrane depolarization via a
voltage-dependent inactivation of ion channels involved in
action potential generation (46). We cannot exclude the
possibility that cGKI modulates Ca
2 inﬂux (25,47)
through voltage-dependent Ca
2-channels (29,48) in the
-cells.
In addition to the ﬁndings summarized above, the gene-
targeted cGKI mice showed an improved glucose clear-
ance in the OGTT (see supplementary Fig. 2) that might be
due to 1) the small initial increase in serum insulin
concentrations during the OGTT; 2) a reduced body fat
mass and FFA; 3) the upregulation of GLUT4 in striated
muscles, and 4) the lack of cGKI in the central nervous
system (49), which could impact islets innervations via, for
example, sympathetic nerve ﬁbers during the OGTT. In-
deed, the importance of cGKI for the biogenesis of adipose
tissue and fat accumulation was recently recognized (50).
It is known that SST released from -cells and from
extra-islet neuroendocrine cells exerts many relevant ac-
tions on islet physiology. Since small amounts of cGKI
were present in -cells of CTR mice, but not in -cells of
cGKI gene-targeted mice (see supplementary Fig. 3), an
altered control of paracrine mechanisms from -cells has
also been taken into account. Together, the lack of cGKI in
the periphery and in -cells of gene-targeted mice might
produce an inappropriate insulin response, which was
noticed upon fasting when these animals were hypergly-
cemic (see Fig. 1).
In conclusion, the presented experiments identify -cell
cGKI as an endogenous modulator of the glucose-induced
inhibition of glucagon release. The loss of islet cGKI
activity in mice leads to an abnormal glucagon secretion,
which is reﬂected by their hyperglycemic fasting
phenotype.
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